HAB Pharmaceuticals & Research Limited and Signature Phytochemical Industries successfully completed their merger, creating a combined pharmaceutical entity with a consolidated turnover of nearly ₹600 crore. The merger was undertaken to streamline operations, strengthen corporate governance and harmonise business systems across both organisations. The integration is also expected to enhance the group’s manufacturing, research and export capabilities.
Expanded Manufacturing and Product Capabilities
HAB Pharmaceuticals brings strong expertise in manufacturing antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular medicines. Meanwhile, Signature Phytochemical Industries has established capabilities in manufacturing and exporting tablets, capsules and topical creams.
As a result of the merger, the combined entity will significantly expand its manufacturing infrastructure and product portfolio across multiple therapeutic segments. The integration is expected to improve operational efficiency while supporting faster product development and commercialisation.
Increased Focus on Specialty and High-Value Drugs
The merged company plans to strengthen its presence in specialty pharmaceuticals with a strategic focus on oncology treatments, autoimmune disorder therapies, chronic disease management and rare disease medications. In addition, the company aims to accelerate research and development activities to support innovation-driven growth and differentiated pharmaceutical offerings.
Global Market Expansion Strategy
Following the merger, the combined entity is now targeting expansion across international markets, particularly in Latin America, Central Asia and Southeast Asia. The company expects the strengthened manufacturing base and broader product portfolio to support its growing export ambitions and improve global market access.
New Manufacturing Facilities to Begin Operations in 2026
As part of its expansion strategy, HAB Pharmaceuticals is commissioning two advanced manufacturing facilities that are expected to begin commercial production by August 2026.
The upcoming facilities include:
*A sterile manufacturing plant focused on semaglutide, prefilled syringes, injectables, vials and lyophilised products
*A fully automated closed-loop Oral Solid Dosage (OSD) manufacturing facility
These new facilities are expected to significantly enhance the company’s production capabilities for high-value and next-generation pharmaceutical products.
Company Focuses on Innovation and Export Growth
Saurabh Agarwal, Director at HAB Pharma, said the company remains focused on innovation, niche pharmaceutical products and strengthening its export and R&D capabilities. He added that the company aims to differentiate itself in the pharmaceutical industry through a diversified product portfolio and a rapid go-to-market strategy.
Merger Strengthens Long-Term Growth Outlook
The merger marks an important milestone for both companies as they work towards building a stronger, innovation-driven pharmaceutical business with enhanced manufacturing scale, research capabilities and international market reach. As reported by thehindubusinessline.com, the combined entity is expected to strengthen its competitive position in the rapidly evolving global pharmaceutical sector while supporting long-term sustainable growth.
